Pancreatic Cancer Drug Market: Leading Treatments & Market Trends
Global Pancreatic Cancer Market reached US$ 2.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 5.7 billion by 2031. The global Pancreatic Cancer market is expected to exhibit a CAGR of 11.1% during the forecast period (2024-2031).
The Pancreatic Cancer market report provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Leveraging a combination of qualitative and quantitative research methods, the company offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://shorturl.at/D6P2y
Pancreatic cancer is a type of cancer that begins in the tissues of the pancreas, an organ located behind the stomach that plays a crucial role in digestion and blood sugar regulation. It typically arises from the cells lining the ducts that carry digestive enzymes (exocrine tumors) or, less commonly, from hormone-producing cells (endocrine tumors). Pancreatic cancer is often aggressive and difficult to detect in its early stages, leading to a poor prognosis.
Forecast Growth Projected:
The Global Pancreatic Cancer Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
List of the Key Players in the Pancreatic Cancer Market:
Myriad Genetics Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Viatris Inc., Boston Scientific Corporation, Clovis Oncology, and GlaxoSmithKline
Industry Development:
In October 2022, Erasca expanded its collaboration with Pfizer to assess ERAS-007 in combination with Pfizer's Ibrance (palbociclib). As part of the extended clinical trial collaboration and supply agreement, both biopharmaceutical companies will conduct clinical proof-of-concept research. The study will focus on evaluating the drug combination in patients with colorectal cancer carrying NRAS and KRAS mutations, as well as those with pancreatic ductal adenocarcinoma harboring KRAS mutations.
Research Methodology
Our research methodology combines both qualitative and quantitative approaches to provide you with a thorough market analysis. We begin by gathering data from trusted industry reports and databases (secondary research), followed by primary research through surveys and interviews with key experts. We then apply advanced statistical tools to analyze the data, uncover trends, and assess market dynamics. Additionally, we use market segmentation and Porter's Five Forces analysis to evaluate competition. This approach ensures that the insights we provide are reliable, actionable, and tailored to support your decision-making process.
Segment Covered in the Pancreatic Cancer Market:
By Treatment Type: Targeted Therapies, Chemotherapy, Surgery, Other Treatments
By End-user: Hospitals, Specialty Clinics, Home care, Others
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian